276 completed, 28 terminated, 23 unknown, 12 withdrawn. 356 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 356 | Completed 276, Terminated 28, Unknown 23, Withdrawn 12, Recruiting 10, Active not recruiting 5, Enrolling by invitation 1, Not yet recruiting 1 |
Follow AstraZeneca: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive Durvalumab, Gemcitabine, Cisplatin - Muscle-Invasive Bladder Cancer (MIBC) | Phase 4 | Not yet recruiting | AstraZeneca | 50 | 2026-10-20 | 2026-10-15 |
| Fasenra: An Asthma Study Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma | Phase 4 | Enrolling by invitation | Endeavor Health | 40 | 2026-07-01 | 2026-09-15 |
| An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd) - Stomatitis | Phase 4 | Recruiting | AstraZeneca | 100 | 2026-06-24 | 2026-10-28 |
| Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. Osimertinib+cisplatin or carboplatin + pemetrexed Edit - Non-small Cell Lung Cancer | Phase 4 | Recruiting | AstraZeneca | 100 | 2026-05-26 | 2026-10-16 |
| Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) Tezepelumab, Placebo - Severe Asthma | Phase 4 | Recruiting | University of Alberta | 100 | 2026-05-11 | 2026-07-17 |
| Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome Ferric Carboxymaltose Injection [Ferinject] - Acute Coronary Syndromes (ACS), Iron Deficiencies | Phase 4 | Recruiting | Fundación para la Investigación del Hospital Clínico de Valencia | 538 | 2026-03-05 | 2026-03-24 |
| Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease Breztri Aerosphere - Moderate to Severe COPD | Phase 4 | Recruiting | AstraZeneca | 166 | 2026-01-20 | 2026-10-02 |
| Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users Anifrolumab - Systemic Lupus Erythematosus | Phase 4 | Recruiting | AstraZeneca | 16 | 2026-01-16 | 2026-09-16 |
| A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation Budesonide/Glycopyrronium/Formoterol Fumarate, Placebo, Metered dose inhaler - Chronic Obstructive Pulmonary Disease, Hyperinflation | Phase 4 | Recruiting | AstraZeneca | 56 | 2025-11-24 | 2026-09-18 |
| Characterizing the Human Airway Immune Response to FluMist Vaccination FluMist, inactivated influenza vaccine, bronchoscopy - Healthy Young Adults, Influenza Vaccines | Phase 4 | Recruiting | Washington University School of Medicine | 30 | 2025-09-09 | 2025-09-17 |
| Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure Acalabrutinib, Investigator's choice of treatment - Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment | Phase 4 | Recruiting | AstraZeneca | 60 | 2025-02-04 | 2026-09-24 |
| Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients Trastuzumab deruxtecan - BREAST CANCER | Phase 4 | Active not recruiting | AstraZeneca | 100 | 2025-01-02 | 2026-09-11 |
| Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients. Budesonide-Formoterol treatment - Cough-Variant Asthma | Phase 4 | Completed | AstraZeneca | 1000 | 2024-10-18 | 2025-09-18 |
| Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma Albuterol/Budesonide, Albuterol - Mild Asthma | Phase 4 | Completed | AstraZeneca | 101 | 2024-09-11 | 2026-02-27 |
| A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease Dapagliflozin - Chronic Kidney Disease | Phase 4 | Active not recruiting | AstraZeneca | 731 | 2024-08-23 | 2026-10-30 |
| Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care Albuterol and budesonide inhalation aerosol - Asthma | Phase 4 | Active not recruiting | AstraZeneca | 1511 | 2024-05-10 | 2026-07-16 |
| Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4 Sodium zirconium cyclosilicate - Hyperkalemia, Diet Modification | Phase 4 | Unknown | Leiden University Medical Center | 16 | 2024-04-29 | 2025-03-06 |
| Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets, Dapagliflozin tablets and Metformin HCl extended-release tablets - Type 2 Diabetes Mellitus (T2DM) | Phase 4 | Completed | AstraZeneca | 633 | 2024-03-15 | 2025-10-31 |
| IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily., External Comparator - COPD | Phase 4 | Withdrawn | AstraZeneca | 2024-01-19 | 2024-02-01 | |
| The Fontan Dapagliflozin Pilot Study Dapagliflozin 10mg Tab - Heart Failure | Phase 4 | Completed | Johns Hopkins University | 29 | 2023-11-08 | 2026-07-22 |
Showing 20 of 356. Sign in to see all of them.
Diabetes Mellitus, Type 2 (58) · Asthma (32) · Pulmonary Disease, Chronic Obstructive (30) · Gastroesophageal Reflux (24) · Schizophrenia (18) · Diabetes Mellitus (17) · Coronary Artery Disease (16) · Acute Coronary Syndrome (13) · Heartburn (12) · Breast Neoplasms (9) · Carcinoma, Non-Small-Cell Lung (9) · Bipolar Disorder (7) · Influenza, Human (7) · Obesity (7) · Heart Failure (6)
dapagliflozin (43) · Esomeprazole (40) · Quetiapine Fumarate (33) · Ticagrelor (32) · Budesonide (29) · Rosuvastatin Calcium (23) · Clopidogrel (21) · Budesonide, Formoterol Fumarate Drug Combination (14) · Formoterol Fumarate (14) · Exenatide (13) · saxagliptin (11) · Aspirin (9) · Metformin (8) · aclidinium bromide (8) · Lansoprazole (7)
United States (122) · China (37) · United Kingdom (35) · Canada (31) · Germany (28) · Spain (26) · South Korea (23) · France (20) · Netherlands (20) · Italy (19) · Sweden (19) · Hungary (16) · Denmark (15) · India (15) · Belgium (12)
Paula Fernstrom (12) · Juan J Badimon, PhD (3) · Lisa Porter, MD (3) · Tomas Andersson, MD (3) · Ana Polanco, MD (2) · Bertil Andersson (2) · Dominick J Angiolillo, MD,PhD (2) · Eric Wittbrodt, PharmD, MPH (2) · Eugenio Cersosimo, MD,PhD (2)
PMID 19897551, PMID 25478944, PMID 29763572, PMID 33369570, PMID 10109801, PMID 10430726, PMID 11401887, PMID 11491153, PMID 11549531, PMID 12204862, PMID 12570114, PMID 14739871, PMID 15591470, PMID 15764761, PMID 15823451, PMID 16055882, PMID 16135736, PMID 16226443, PMID 1627164, PMID 16271642, PMID 16271643, PMID 16478839, PMID 16687712, PMID 16959033, PMID 17305763, PMID 17698615, PMID 17898099, PMID 17955081, PMID 18031595, PMID 18270751, PMID 18493207, PMID 18535816, PMID 18550609, PMID 18721170, PMID 18786299, PMID 18842256, PMID 18924451, PMID 18955731, PMID 18990678, PMID 19049375, PMID 19157776, PMID 19358783, PMID 19601705, PMID 19644045, PMID 19733449, PMID 19812399, PMID 19878590, PMID 20199136, PMID 20230209, PMID 20395358
2014 (4), 2015 (4), 2016 (4), 2019 (3), 2017 (2), 2018 (2), 2009 (1), 2023 (1), 2025 (1), R01HL048013 (1)